Age | At risk | hrHPV | Bivalent vaccine types^{a} | Nonbivalent vaccine types^{b} | Polyvalent vaccine types^{c} | Nonpolyvalent vaccine types^{d} | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
POBASCAM | |||||||||||
29–33 | 1,899 | 108 | 5.69 (4.69–6.83) | 44 | 2.32 (1.67–3.10) | 77 | 4.05 (3.22–5.04) | 88 | 4.63 (3.73–5.68) | 34 | 1.79 (1.24–2.49) |
34–38 | 3,671 | 125 | 3.41 (2.84–4.04) | 48 | 1.31 (0.97–1.73) | 89 | 2.42 (1.95 -2.98) | 94 | 2.56 (2.07–3.12) | 45 | 1.23 (0.90–1.64) |
39–43 | 3,251 | 68 | 2.09 (1.63–2.64) | 25 | 0.77 (0.50–1.13) | 47 | 1.46 (1.06–1.92) | 47 | 1.45 (1.06–1.92) | 24 | 0.74 (0.48–1.10) |
44–48 | 3,174 | 56 | 1.76 (1.34–2.29) | 13 | 0.41 (0.22–0.70) | 45 | 1.42 (1.04–1.89) | 34 | 1.07 (0.74–1.49) | 24 | 0.76 (0.49–1.12) |
49–53 | 2,639 | 45 | 1.71 (1.25–2.28) | 16 | 0.61 (0.35–9.83) | 30 | 1.14 (0.77–1.62) | 31 | 1.17 (0.80–1.66) | 15 | 0.57 (0.32–0.94) |
54–56 | 2,037 | 21 | 1.03 (0.64–1.57) | 8 | 0.39 (0.17–0.77) | 13 | 0.64 (0.34–1.09) | 16 | 0.79 (0.45–1.27) | 5 | 0.25 (0.08–0.57) |
Total | 16,671 | 423 | 2.54 (2.30–2.78) | 154 | 0.92 (0.78–1.08) | 301 | 1.81 (1.61–2.02) | 310 | 1.86 (1.66–2.08) | 147 | 0.88 (0.75–1.04) |
Linear effect: regression coefficient (SE)^{e} | −0.066 (0.007)^{h} | −0.079 (0.012)^{h} | −0.068 (0.008)^{h} | −0.076 (0.008)^{h} | −0.063 (0.012)^{h} | ||||||
Nonlinear effect: regression coefficient (SE)^{f} | 0.002 (<0.001)^{i} | 0.003 (0.001)^{i} | 0.001 (0.001) | 0.003 (0.001)^{i} | <0.001 (0.002) | ||||||
NTCC | |||||||||||
24–28 | 748 | 65 | 8.69 (6.77–10.94) | 26 | 3.48 (2.28–5.05) | 47 | 6.28 (4.65–8.27) | 46 | 6.15 (4.54–8.12) | 28 | 3.74 (2.5–5.36) |
29–33 | 961 | 53 | 5.52 (4.16–7.15) | 28 | 2.91 (1.94–4.18) | 32 | 3.33 (2.29–4.67) | 44 | 4.58 (3.35–6.1; 44) | 15 | 1.56 (0.88–2.56) |
34–38 | 1222 | 40 | 3.27 (2.35–4.43) | 10 | 0.82 (0.39–1.5) | 23 | 2.62 (1.8–3.68) | 27 | 2.21 (1.46–3.2; 27) | 18 | 1.47 (0.88–2.32) |
39–43 | 1123 | 29 | 2.58 (1.74–3.69) | 10 | 0.89 (0.43–1.63) | 23 | 2.05 (1.3–3.06) | 15 | 1.34 (0.75–2.19; 15) | 15 | 1.34 (0.75–2.19) |
44–48 | 1112 | 24 | 2.16 (1.39–3.19) | 8 | 0.72 (0.31–1.41) | 18 | 1.62 (0.96–2.55) | 12 | 1.08 (0.56–1.88; 12) | 12 | 1.08 (0.56–1.88) |
49–53 | 901 | 12 | 1.33 (0.69–2.31) | 4 | 0.44 (0.12–1.13) | 10 | 1.11 (0.53–2.03) | 8 | 0.89 (0.38–1.74; 8) | 4 | 0.44 (0.12–1.13) |
54–56 | 667 | 8 | 1.2 (0.52–2.35) | 4 | 0.6 (0.16–1.53) | 6 | 0.9 (0.33–1.95) | 7 | 1.05 (0.42–2.15; 7) | 3 | 0.45 (0.09–1.31) |
57–60 | 700 | 2 | 0.29 (0.03–1.03) | 0 | 0 (0–0.53) | 2 | 0.29 (0.03–1.03) | 1 | 0.14 (0–0.79; 1) | 1 | 0.14 (0–0.79) |
Total | 7434 | 233 | 3.13 (2.75–3.56) | 90 | 1.21 (0.97–1.49) | 170 | 2.29 (1.96–2.65) | 160 | 2.15 (1.83–2.51; 160) | 96 | 1.29 (1.05–1.57) |
Linear effect: regression coefficient (SE)^{e}^{,}^{g} | −0.068 (0.011)^{h} | −0.083 (0.018)^{h} | −0.057 (0.012)^{h} | −0.084 (0.014)^{h} | −0.049 (0.016)^{i} | ||||||
Nonlinear effect: regression coefficient (SE)^{f}^{,}^{g} | 0.001 (0.001) | 0.005 (0.002)^{i} | <0.001 (0.002) | 0.004 (0.002)^{i} | −0.002 (0.002) |
↵^{a}Bivalent vaccine types includes HPV types 16 and 18.
↵^{b}Nonbivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
↵^{c}Polyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52, and 58.
↵^{d}Nonpolyvalent vaccine types includes HPV types 35, 39, 51, 56, 59, and 68. The classification in HPV types is not mutually exclusive and totals of bivalent + nonbivalent and polyvalent + nonpolyvalent types exceed the 100% as a result of multiple type infections.
↵^{e}Regression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable.
↵^{f}Regression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable.
↵^{g}Restricted to the same age range as POBASCAM (29–56 years).
↵^{h}P < 0.001.
↵^{i}P < 0.05.